Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 7Suspended 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 660Carcinoma, Non-Small-Cell Lung 454Prostatic Neoplasms 384Neoplasms 376Lung Neoplasms 261Multiple Myeloma 246Colorectal Neoplasms 231Neoplasm Metastasis 214Melanoma 202Leukemia, Myeloid, Acute 165Ovarian Neoplasms 163Pancreatic Neoplasms 155Carcinoma, Renal Cell 141Squamous Cell Carcinoma of Head and Neck 137Lymphoma 134Brain Neoplasms 132Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 123Lymphoma, Non-Hodgkin 123Carcinoma, Hepatocellular 117Head and Neck Neoplasms 114Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 107Stomach Neoplasms 106Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Uterine Cervical Neoplasms 100Hematologic Neoplasms 99Lymphoma, Follicular 95Sarcoma 93

Interventions

Vorinostat 1Lenalidomide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × GATA2 Deficiency × 1 year × Clear all
NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡